ProQR Partners with Ginkgo Bioworks for AI-Driven RNA Editing Advancements
ProQR Therapeutics will utilize Ginkgo Bioworks' Nebula autonomous lab to enhance its Axiomer RNA editing platform. The partnership aims to scale AI-enabled discovery processes, with a clinical trial application for a candidate expected in mid-2026.
Theia Market Signal Identification - AI Assisted
ProQR Therapeutics will leverage Ginkgo Bioworks' Nebula autonomous lab to accelerate high-throughput data generation for its Axiomer RNA editing platform. The partnership includes a strategic equity investment from Ginkgo, enhancing collaboration beyond traditional contract research organization (CRO) models.
ProQR anticipates its first AI-discovered candidate to enter clinical trials in mid-2026, with initial data expected by year-end. The collaboration aims to fill the gap between standardized outsourced services and in-house lab work, allowing for more flexible experimental protocols. This approach could redefine drug discovery methodologies by integrating automation with unique experimental designs.
Comments